A new trading day began on November 20, 2023, with ImmunityBio Inc (NASDAQ: IBRX) stock priced at $4.22, down -2.17% from the previous day of trading. During the day, the shares moved up to $4.49 and dropped to $3.93 before settling in for the closing price of $4.14. IBRX’s price has ranged from $1.21 to $7.10 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 164.24%. Meanwhile, its annual earnings per share averaged 10.58%. With a float of $130.77 million, this company’s outstanding shares have now reached $421.57 million.
Considering the fact that the conglomerate employs 725 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -9980.00, operating margin of -146090.42, and the pretax margin is -173869.17.
ImmunityBio Inc (IBRX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of ImmunityBio Inc is 80.41%, while institutional ownership is 7.50%. The most recent insider transaction that took place on Jun 05, was worth 198,023. In this transaction Director of this company bought 71,915 shares at a rate of $2.75, taking the stock ownership to the 71,915 shares. Before that another transaction happened on Jun 02, when Company’s Director bought 25,000 for $2.83, making the entire transaction worth $70,700. This insider now owns 25,000 shares in total.
ImmunityBio Inc (IBRX) Recent Fiscal highlights
In its latest quarterly report, released on 9/29/2023, the company reported earnings of -$0.19 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -173569.58. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.70% during the next five years compared to 2.79% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
Here are ImmunityBio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4828.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of ImmunityBio Inc (IBRX)
Compared to the last year’s volume of 4.24 million, its volume of 4.98 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 85.72%. Additionally, its Average True Range was 0.41.
During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 86.42%, which indicates a significant increase from 75.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 126.28% in the past 14 days, which was higher than the 119.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.21, while its 200-day Moving Average is $2.40. Nevertheless, the first resistance level for the watch stands at $4.38 in the near term. At $4.72, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.94. If the price goes on to break the first support level at $3.82, it is likely to go to the next support level at $3.60. Now, if the price goes above the second support level, the third support stands at $3.26.
ImmunityBio Inc (NASDAQ: IBRX) Key Stats
With a market capitalization of 2.70 billion, the company has a total of 667,705K Shares Outstanding. Currently, annual sales are 240 K while annual income is -416,570 K. The company’s previous quarter sales were 80 K while its latest quarter income was -95,580 K.